OBI Phase 3 LANTERN trial shows 40.5% reduction in 30-day surgical site infections

Ondine Biomedical’s Phase 3 LANTERN trial reported a 40.5% reduction in 30-day surgical site infections using nasal photodisinfection. The company said the results had strong statistical support, with no significant adverse events; regulatory discussions and further analyses are ongoing.